Company profile
NeuroSense Therapeutics Ltd.
NASDAQ:NRSNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Celecoxib | approved | — | 6 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05436678 | phase1 | completed | 2022-07-26 | 2022-08-19 | NeuroSense Therapeutics Ltd. | A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject |
| NCT06185543 | phase2 | terminated | 2023-11-19 | 2025-09-30 | NeuroSense Therapeutics Ltd. | A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. |
| NCT05357950 | phase2 | completed | 2022-05-31 | 2023-11-02 | NeuroSense Therapeutics Ltd. | A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS |
| NCT05232461 | phase1 | completed | 2022-04-08 | 2022-04-21 | NeuroSense Therapeutics Ltd. | A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects |
| NCT04090684 | phase1 | completed | 2019-12-09 | 2021-09-27 | NeuroSense Therapeutics Ltd. | Ciprofloxacin/Celecoxib Combination in Patients With ALS |
FDA applications (0)
No records yet.